Clinical Study

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study

Table 2

Toxicity events according to grade and level of dose, described per patient and per cycle. (a) Phase I. (b) Phase II (VRB 40 mg + CAPE 500 mg 3).
(a)

Level I
VRB = 20 mg
Level II
VRB 30 mg
Level III
VRB 40 mg
Total
Per PtsPer cyclePer ptsPer cyclePer ptsPer cyclePer ptsPer cycle

Events G1
 Abdominal pain0023515718
 Nausea112416411
 Gastric pain00113344
 Diarrhea00002424
 Vomiting00001111
 Stomatitis00111122
 Asthenia00112233
 Dyspnea11001122
 Dysgeusia00001111
 Anemia00000222
 Leukopenia00000222
 Increase in
 transaminases
00110021
 Total2281117383251
Events G2
 Abdominal pain00001111
 Nausea00122234
 Asthenia00123446
 Constipation22000022
 Total2224671013

(b)

Per ptsPer cycle

Events G1
 Abdominal pain314
 Nausea-vomiting820
 Gastric pain44
 Diarrhea58
 Stomatitis22
 Asthenia415
 Anemia34
 Neutropenia
 Thrombocytopenia
 Leukopenia411
 Transaminitis
 Dyspnoea11
 Neuropathy34
 Hand-foot syndrome11
 Nail changes11
 Muscular pain35
 Total4090
Events G2
 Abdominal pain44
 Nausea-vomiting4*4
 Diarrhea1
 Stomatitis1*1
 Asthenia810
 Dysgeusia11
 Neutropenia1
 Anemia13
 Hand-foot syndrome12
 Nail changes22
 Total2229
Events G3
 Neutropenia1**2
 Thrombocytopenia11
 Leukopenia
 Neuropathy1***2
 Hand-foot syndrome1****1
 Gamma GT increase11
 Total57
Events G4
 Neutropenia11
 Febrile neutropenia11
 Leukopenia22
 Total44

In 1 patient vomiting and stomatitis Grade 2 determined a dose reduction of VRB at 20 mg thrice a week.
In 1 patient Grade 3 neutropenia was associated to Grade 1 Leukopenia; no dose reduction was required.
Grade 3 neuropathy determined a dose reduction of VRB at 20 mg thrice a week.
Grade 3 hand-foot syndrome determined a dose reduction of CAPE at 500 mg twice a day, until complete recovery to Grade 1.
See details in the text.